Skip to content
Back to meeting Original
SEOM路 @_SEOM 路 X路路 8 hours agoScore70

SAFFRON

Body

馃敩 #ESMO26 | SAFFRON (LBA6): osimertinib + savolitinib mejora SLP (7,6 vs. 5,4 meses) y SG (17,8 vs. 12,9) frente a quimioterapia en CPNM EGFRm con alteraciones MET tras progresi贸n a osimertinib.

馃┖ El Dr. @javierDcastro , presidente de @_SEOM , analiza los resultados de este estudio presentado en Sesi贸n Presidencial del Congreso @myESMO

15 views 路 0 likes 路 0 reposts 路 0 replies

Source: SEOM 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.